Related Experiment Video
Updated: May 29, 2025

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2
Adam D Longhurst1,2, Kyle Wang3,4, Harsha Garadi Suresh3
1University of California, San Francisco, San Francisco, United States.
Abstract:
Progression through the G1 phase of the cell cycle is the most highly regulated step in cellular division. We employed a chemogenetic approach to discover novel cellular networks that regulate cell cycle progression. This approach uncovered functional clusters of genes that altered sensitivity of cells to inhibitors of the G1/S transition. Mutation of components of the Polycomb Repressor Complex 2 rescued proliferation inhibition caused by the CDK4/6 inhibitor palbociclib, but not to inhibitors of S phase or mitosis. In addition to its core catalytic subunits, mutation of the PRC2.1 accessory protein MTF2, but not the PRC2.2 protein JARID2, rendered cells resistant to palbociclib treatment. We found that PRC2.1 (MTF2), but not PRC2.2 (JARID2), was critical for promoting H3K27me3 deposition at CpG islands genome-wide and in promoters. This included the CpG islands in the promoter of the CDK4/6 cyclins CCND1 and CCND2, and loss of MTF2 lead to upregulation of both CCND1 and CCND2. Our results demonstrate a role for PRC2.1, but not PRC2.2, in antagonizing G1 progression in a diversity of cell linages, including chronic myeloid leukemia (CML), breast cancer, and immortalized cell lines.
Insights
Polycomb Repressor Complex 2 (PRC2.1) protein MTF2 is crucial for cell cycle progression. Loss of MTF2 confers resistance to CDK4/6 inhibitors by upregulating CCND1 and CCND2, impacting cancer cell proliferation.
Area of Science:
- Cell Biology
- Molecular Biology
- Epigenetics
Background:
- Cell cycle progression, particularly the G1 phase, is tightly regulated.
- Identifying novel regulators of cell cycle control is essential for understanding cellular division and developing targeted therapies.
Purpose of the Study:
- To discover novel cellular networks regulating cell cycle progression using a chemogenetic approach.
- To investigate the role of Polycomb Repressor Complex 2 (PRC2) components in cell cycle regulation and response to G1/S transition inhibitors.
Main Methods:
- Chemogenetic screening to identify gene clusters affecting sensitivity to G1/S inhibitors.
- Mutation analysis of Polycomb Repressor Complex 2 (PRC2) components, including MTF2 and JARID2.
- Assays to assess H3K27me3 deposition and gene expression of CCND1 and CCND2.
Main Results:
- Mutation of PRC2 components rescued proliferation inhibition by the CDK4/6 inhibitor palbociclib.
- Loss of PRC2.1 component MTF2, but not PRC2.2 component JARID2, conferred resistance to palbociclib.
- MTF2 is essential for H3K27me3 deposition at CpG islands, including promoters of CCND1 and CCND2, and its loss upregulated these cyclins.
Conclusions:
- PRC2.1, specifically MTF2, antagonizes G1 phase progression in various cell lineages.
- MTF2's role in regulating CCND1/CCND2 expression is critical for sensitivity to CDK4/6 inhibition.
- These findings highlight PRC2.1 as a potential therapeutic target in cancers driven by CDK4/6 pathway dysregulation.
Related Concept Videos
Negative Regulator Molecules
Inhibition of Cdk Activity
Positive Regulator Molecules
Anaphase Promoting Complex
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
Separation of Sister Chromatids
At the onset of anaphase, separase, a proteolytic enzyme, is...

